Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. AAPL
6. GOOGL
7. ORCL
8. CMG
9. CRGY
10. SPY

Go back to Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint

Sanofi (SNY) Announces LixiLan-O Phase II Met Primary Endpoint in Type 2 Diabetes

July 29, 2015 7:02 AM EDT

Sanofi (NYSE: SNY) announced that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. Overall, the fixed-ratio combination had a safety profile reflecting those of lixisenatide and insulin glargine 100 units/mL.

"Meeting the primary objective of this important Phase III study highlights the potential clinical value of... More